ArticleBlood cancer journal2022
A simple additive staging system for newly diagnosed multiple myeloma.
Article in Blood cancer journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07045168 (Risk-adapted Therapeutic Strategy in +1q NDMM： a Prospective, Multicenter Study), which is not on this map. Cited by 60 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Risk-adapted Therapeutic Strategy in +1q NDMM： a Prospective, Multicenter Study
Who cites it
60 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Guideline
- Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review.Blood cancer journal · 2024Pooled it
- Molecular Long-Term Analysis of the GMMG-HD4 Trial in Multiple Myeloma-Patterns of Association of Chromosomal Aberrations with Response and Proliferation Determining Survival in Selecting Treatments in View of Limited Resources in Low- and Middle-Income Countries.International journal of molecular sciences · 2024Trial
- Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells.Blood cancer journal · 2024Trial
- Cytogenetics-based clinical trajectories in patients with MRD negativity post autologous transplant for multiple myeloma.Leukemia · 2026Article
- Real World Data and Its Impact on the Management of Plasma Cell Dyscrasias.Current hematologic malignancy reports · 2026Review
- Extracellular Vesicles as Master Regulators of Immune Modulation in Multiple Myeloma.International journal of molecular sciences · 2026Review
- Programmed cell death protein 1 (PD-1) / programmed cell death ligand 1 (PD-L1) in multiple myeloma.Journal of the Egyptian National Cancer Institute · 2026Observational
- Prognostic Significance of Isolated Beta 2-Microglobulin Elevation in Thai Multiple Myeloma: Impact of Renal Function Assessment.Journal of hematology · 2026Article
- Advances in the application of frailty scoring in the diagnosis and management of elderly patients with multiple myeloma (Review).Oncology reports · 2026Review
- Shaping the future of multiple myeloma with artificial intelligence and digital twins: from concept to clinic.Frontiers in digital health · 2026Review
- Chromosome 1q alterations in transplant-eligible multiple myeloma: clinical impact of copy number and co-occurring high-risk cytogenetic features.Frontiers in oncology · 2026Article
- Article
- MASS-4 is more suitable than MASS-3 for prognostic stratification in transplant-eligible patients with newly diagnosed multiple myeloma.Annals of medicine · 2025Article
- Prognostic Implications of Thrombocytopenia in Chinese Patients With Newly Diagnosed Multiple Myeloma.Cancer medicine · 2025Article
- Current risk stratification and staging of multiple myeloma and related clonal plasma cell disorders.Leukemia · 2025Review
- Prognostic potential of albumin to fibrinogen ratio in multiple myeloma patients.Annals of hematology · 2025Article
- Identification of treatment effect modifiers and prognostic factors in newly diagnosed and relapsed or refractory multiple myeloma.Journal of comparative effectiveness research · 2025Article
- The past, present, and future of myeloma staging and risk prognostication.The oncologist · 2025Review
- Machine learning risk stratification strategy for multiple myeloma: Insights from the EMN-HARMONY Alliance platform.HemaSphere · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
Abstract
Risk stratification in multiple myeloma is important for prognostication, patient selection for clinical trials, and comparison of treatment approaches. We developed and validated a staging system that incorporates additional FISH abnormalities not included in the R-ISS and reflects the additive effects of co-occurring high-risk disease features. We first evaluated the prognostic value of predefined cytogenetic and laboratory abnormalities in 2556 Mayo Clinic patients diagnosed between February 2004 and June 2019. We then used data from 1327 patients to develop a risk stratification model and validated this in 502 patients enrolled in the MMRF CoMMpass study. On multivariate analysis, high-risk IgH translocations [risk ratio (RR): 1.7], 1q gain/amplification (RR: 1.4), chromosome17 abnormalities (RR: 1.6), ISS III (RR: 1.7), and elevated LDH (RR: 1.3) were independently associated with decreased overall survival (OS). Among 1327 evaluable patients, OS was 11.0 (95% CI: 9.2-12.6), 7.0 (95% CI: 6.3-9.2), and 4.5 (95% CI: 3.7-5.2) years in patients with 0 (stage I), 1 (stage II), and ≥2 (stage III) high-risk factors, respectively. In the MMRF cohort, median OS was 7.8 (95% CI: NR-NR), 6.0 (95% CI: 5.7-NR), and 4.3 (95% CI: 2.7-NR) years in the 3 groups, respectively (P < 0.001). This 5-factor, 3-tier system is easy to implement in practice and improves upon the current R-ISS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.